Olema Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
OLMA$7.27-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(Amounts in thousands)
| Years Ended December 31, | ||||
|---|---|---|---|---|
| 2024 · 2023 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $ | (129,474) | $ | (96,655) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation and amortization expense | 393 | 377 | ||
| Loss on disposal of equipment | 9 | 111 | ||
| Non-cash lease expense | 1,150 | 1,297 | ||
| Non-cash interest income on marketable securities | (8,175) | (5,524) | ||
| Stock-based compensation expense, including employee stock purchase plan expense | 22,582 | 17,256 | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other current assets | (429) | 694 | ||
| Other assets and long-term deposits | (2,957) | (5,324) | ||
| Accounts payable | 2,510 | 2,324 | ||
| Other current liabilities | 11,202 | 2,948 | ||
| Operating lease liabilities | (1,162) | (1,231) | ||
| Net cash used in operating activities | (104,351) | (83,727) | ||
| Cash flows from investing activities: | ||||
| Maturities of marketable securities | 301,592 | 250,760 | ||
| Purchases of marketable securities | (394,959) | (255,625) | ||
| Purchase of equipment | (159) | — | ||
| Disposal of fixed assets | — | 14 | ||
| Net cash used in investing activities | (93,526) | (4,851) | ||
| Cash flows from financing activities: | ||||
| Proceeds from equity private placement, net of issuance costs of $6,498 | 243,501 | 129,736 | ||
| Proceeds from at-the-market offering, net of issuance costs of $166 | 22,787 | — | ||
| Proceeds from exercise of stock options | 1,671 | 2,629 | ||
| Proceeds from issuance of common stock under the ESPP plan | 859 | 1,050 | ||
| Net cash provided by financing activities | 268,818 | 133,415 | ||
| Net increase in cash and cash equivalents | 70,941 | 44,837 | ||
| Cash and cash equivalents at beginning of period | 68,539 | 23,702 | ||
| Cash and cash equivalents at end of period | $ | 139,480 | $ | 68,539 |
| Supplemental disclosure of non-cash investing and financing activities: | ||||
| Issuance costs for equity private placement not paid in cash by the end of period | $ | 6,500 | $ | — |
| Exchange common stock shares for pre-funded warrants | $ | 31,054 | $ | — |
| Research and development project deposit applied against final study invoices | $ | 748 | $ | — |
| System implementation cost included in other current liabilities | $ | (337) | $ | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.